2022 Fiscal Year Final Research Report
Improving effects of Haskap fruit extracts on primary biliary cholangitis and primary sclerosing cholangitis
| Project/Area Number |
19K20122
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 59040:Nutrition science and health science-related
|
|---|
| Research Institution | International University of Health and Welfare |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | PSC / PBC / Haskap / Fruit extract / animal model / Low dose / Medium dose / High dose |
|---|
| Outline of Final Research Achievements |
In the first study, investigating the effects of haskap fruit extract on a mouse model of primary biliary cholangitis, showed improved serological markers of hepatocellular injury, cholestasis, cholangitis. and histopathological findings of fibrosis in the medium- and high-dose haskap fruit extracts administrating groups. Total T-lymphocyte infiltration in liver tissue was significantly suppressed in the medium-dose haskap administration group.
In the second study, investigating the effects of haskap fruit extract on primary sclerosing cholangitis model mice, the serum levels of ALT were significantly improved by administration of low-dose haskap fruit extract, and ALP levels were significantly improved by administration of high-dose haskap fruit extract. Total bilirubin levels were significantly lower in the high-dose group than in the low-dose haskap group.
|
| Free Research Field |
59040
|
| Academic Significance and Societal Importance of the Research Achievements |
The Haskap fruit extract improves PBC and PSC in model mice through reducing inflammation, bile duct damage, or fibrosis. Thus, Based on above findings we believe that this our preliminary achievement will lead to the development of new therapeutic agents for PBC and PSC.
|
